Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
Board approves fundraise of Rs 1500 crore
The transaction is expected to close in the Q4FY22
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
CDSCO to fast-track trials and approval for COVID19 vaccine
Subscribe To Our Newsletter & Stay Updated
